Objective:To evaluate the efficacy and safety of Xuesaitong Injection in the treatment of angina pectoris.Methods:CNKI and WAN were retrieved Fang,VIP,CBMdisc,PubMed and Cochrane libraries published a randomized contr...Objective:To evaluate the efficacy and safety of Xuesaitong Injection in the treatment of angina pectoris.Methods:CNKI and WAN were retrieved Fang,VIP,CBMdisc,PubMed and Cochrane libraries published a randomized controlled trial of Xuesaitong Injection in the treatment of angina pectoris of coronary heart disease from the beginning of the establishment of the database to January 2020.29 cases were finally included in the study through layer by layer selection.The total sample size was 2560 cases,including 1307 cases in the experimental group and 1253 cases in the control group.The data collected were meta analyzed by Revman 5.3 software.Results:on the basis of routine western medicine treatment,Xuesaitong injection was added in the clinical comprehensive effective rate([RR=1.31;95%CI(1.25,1.39)]),angina symptom improvement rate([RR=1.16;95%CI(1.07,1.26)]),ECG improvement rate([RR=1.25;95%CI(1.14,1.38)]),angina attack times([RR=-2.49;95%CI(-3.27,-1.70)]);fibrinogen([MD=-0.61;95%CI(-0.77,-0.45)]),plasma(specific)viscosity([MD=-0.19;95%CI(-0.22,-0.16)]),hematocrit([MD=-0.04;95%CI(-0.05,-0.03)])and other aspects were superior to the conventional treatment of Western medicine,the difference was statistically significant.Safety aspect:the reported adverse reactions were mild and tolerable events such as headache,dizziness,flush,etc.,no serious adverse events,and no separation from the report was found.Conclusion:on the basis of conventional western medicine,Xuesaitong injection can effectively improve the clinical efficacy,and has a high safety.However,due to the low quality of the included study and the small sample size,there is a potential bias in the study;therefore,the application and promotion of the research conclusions need to be cautious,and need to be further verified by more large sample,multicenter,double-blind clinical randomized controlled trials.展开更多
Objective To evaluate the effect of Xuesai-tong injection (XSTI, 血塞通注射液 , a preparation of Panax Notoginseng) as auxilliary treatment of severe craniocerebral injury. Methods Eighty-seven patients with severe cr...Objective To evaluate the effect of Xuesai-tong injection (XSTI, 血塞通注射液 , a preparation of Panax Notoginseng) as auxilliary treatment of severe craniocerebral injury. Methods Eighty-seven patients with severe craniocerebral injury were selected and randomly divided into the treated group (n=44) and the control group (n = 43), they were treated with conventional treatment, and XSTI was given additionally to the treated group. Intracranial pressure (ICP) and Glasgow coma score (GCS) of all patients were measuredafter 1 or 2-week treatment, and Glasgow outcome scale (GOS) of them was determined 3 months later. Then the therapeutic effect in the two groups were compared. Results After treatment, the ICP was lower, GCS higher and GOS better in the treated group than those in the control group significantly, all showing statistical significance (P<0.05). Conclusion XSTI has marked clinical therapeutic effect in treating patients with severe craniocerebral injury.Original article on CJITWM (Chin) 2004 ;23 (3): 213展开更多
目的:观察丁苯酞注射液联合血塞通注射液治疗急性脑梗死的临床疗效,同时采用MRI灌注成像从影像学角度进行疗效评价。方法:将符合纳入标准的80例急性脑梗死病人按随机数字表法随机分为对照组与治疗组,各40例。两组患者入院后均按照临床...目的:观察丁苯酞注射液联合血塞通注射液治疗急性脑梗死的临床疗效,同时采用MRI灌注成像从影像学角度进行疗效评价。方法:将符合纳入标准的80例急性脑梗死病人按随机数字表法随机分为对照组与治疗组,各40例。两组患者入院后均按照临床路径开展治疗,均给予降压、降糖、调脂、营养神经、抗血小板聚集等药物。对照组在此基础上联合应用丁苯酞氯化钠注射液100 mL静脉滴注治疗,观察组则在对照组基础上联合血塞通注射液200 mg加入5%葡萄糖注射液250 mL静脉滴注。对比两组患者入院当天、分组治疗10 d后的美国国立卫生研究院卒中量表(The National Institutes of Health Stroke Scale,NIHSS)评分、日常生活能力Barthel指数(Barthel Index,BI)评分以及给予MRI灌注成像相关指标变化。结果:治疗组治疗总有效率明显高于对照组(97.50%vs 77.50%,P<0.05);治疗后,两组NIHSS评分均较治疗前下降,BI评分均较治疗前上升,差异有统计学意义(P<0.05),且治疗组优于对照组(P<0.05);治疗后,两组感兴趣区的衰减指数均明显降低,平均扩散系数明显升高(P<0.05),且治疗组数据均明显优于对照组(P<0.05);分组治疗后,治疗组患者的脑血容量、脑血流量均明显优于对照组(P<0.05);基于Pearson相关性分析可知,治疗组治疗后平均扩散系数(r=-0.503,r=0.482)、衰减指数(r=-0.487,r=0.414)、脑血容量(r=-0.527,r=0.402)及脑血流量(r=-0.625,r=0.516)与NIHSS评分和BI评分均有显著相关性(P<0.05)。结论:基于多模态MRI成像结果可证实丁苯酞注射液联合血塞通注射液治疗急性脑梗死的效果良好,展现治疗前后病灶区域平均扩散系数和衰减指数的差异变化,直观反映容积比各向异性和部分各向异性的变化以及脑血流量和脑血容量的改善,且上述指标的变化与急性脑梗死患者的神经功能缺损程度和日常生活能力变化的相关性良好,提示多模态MRI成像结果可作为急性脑梗死的疗效评价提供可靠参考。展开更多
Traumatic brain injury (TBI) is one of the most common diseases in clinical neurosurgery characterized with high incidence rate, mortality and many complications. Objectives: The purpose of this study is to explore th...Traumatic brain injury (TBI) is one of the most common diseases in clinical neurosurgery characterized with high incidence rate, mortality and many complications. Objectives: The purpose of this study is to explore the roles of Xuesaitong in the therapeutic effect of brain trauma and alteration of expression in Bax, a kind of promoting apoptosis factor. Methods: The rat traumatic brain injury models were established by using modified free falling body impact method. Thereafter, Xuesaitong was employed to be administered to TBI rats, and NSS Score Rating Scale was used to evaluate the effect of Xuesaitong. Moreover, real-time PCR was used to detect the Bax expression changes before and after the Xuesaitong administration. Results: Xuesaitong could accelerate the neurofunctional recovery of TBI rats, accompanied by NSS Scores significant decrease. Simultaneously, it also could inhibit the expression of Bax factor. Conclusions: Xusaitong could markedly ameliorate TBI restoration, in which it promotes the neurofunctional recovery, and at the same time it inhibits the expression of Bax.展开更多
Objective： To investigate the neuro-protective effect of Xuesaitong Injection （血塞通注射液, XST） on brain inflammatory response after transient focal cerebral ischemia/reperfusion in rats. Methods： Focal cerebral...Objective： To investigate the neuro-protective effect of Xuesaitong Injection （血塞通注射液, XST） on brain inflammatory response after transient focal cerebral ischemia/reperfusion in rats. Methods： Focal cerebral ischemia/reperfusion models of male rats were induced by transient occlusion for 2 h of middle cerebral artery （MCA） which was followed by 24 h reperfusion. XST was administered through intraperitoneal injection of 25 mg/kg or 50 mg/kg at 4 h after the onset of ischemia. After reperfusion for 24 h, the neurological function score was evaluated, the brain edema was detected with dry-wet weight method, the myeloperoxidase （MPO） activity and the expression of intercellular adhesion molecule-1 （IOAM-l） of ischemic cerebral cortex and caudate putamen was determined by spectrophotometry and immunohistochemistry respectively. Results： XST not only lowered neurological function score at the dose of 50 mg/kg, but reduced brain edema and inhibited MPO activity and IOAM-1 expression as compared with the ischemia/reperfusion model group （P〈0.01）. Conclusion： XST has a definite effect on inhibiting the expression of IOAM-1 and neutrophil infiltration in rats with cerebral ischemia/reperfusion when treatment started at 4 h after ischemia onset, and also attenuates inflammation in the infarcted cerebral area.展开更多
目的探讨血塞通冻干粉联合硫辛酸治疗糖尿病伴脑梗死的临床效果。方法选取2019年7月至2021年7月收治的110例糖尿病伴脑梗死患者为研究对象,根据入院单双号将其分为对照组(55例,丹参注射液+硫辛酸)和研究组(55例,血塞通冻干粉+硫辛酸)。...目的探讨血塞通冻干粉联合硫辛酸治疗糖尿病伴脑梗死的临床效果。方法选取2019年7月至2021年7月收治的110例糖尿病伴脑梗死患者为研究对象,根据入院单双号将其分为对照组(55例,丹参注射液+硫辛酸)和研究组(55例,血塞通冻干粉+硫辛酸)。比较两组的治疗效果。结果研究组的治疗总有效率高于对照组(P<0.05)。治疗后,研究组的空腹血糖(FBG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)、胰岛素抵抗指数(HOMA-IR)、可溶性细胞间黏附分子-1(sICAM-1)、白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、美国国立卫生院卒中量表(NIHSS)评分、全血黏度、红细胞压积、红细胞最大聚集指数及纤维蛋白原水平低于对照组,胰岛素分泌指数(HOMA-β)高于对照组(P<0.05)。结论相较于丹参注射液,血塞通冻干粉联合硫辛酸治疗糖尿病伴脑梗死的效果更优,其可改善胰岛功能,调节血糖水平及血液流变学指标,促进神经功能恢复。展开更多
基金“Major new drug creation” of 13th five-year science and technology major project (No.2018ZX09734-002)。
文摘Objective:To evaluate the efficacy and safety of Xuesaitong Injection in the treatment of angina pectoris.Methods:CNKI and WAN were retrieved Fang,VIP,CBMdisc,PubMed and Cochrane libraries published a randomized controlled trial of Xuesaitong Injection in the treatment of angina pectoris of coronary heart disease from the beginning of the establishment of the database to January 2020.29 cases were finally included in the study through layer by layer selection.The total sample size was 2560 cases,including 1307 cases in the experimental group and 1253 cases in the control group.The data collected were meta analyzed by Revman 5.3 software.Results:on the basis of routine western medicine treatment,Xuesaitong injection was added in the clinical comprehensive effective rate([RR=1.31;95%CI(1.25,1.39)]),angina symptom improvement rate([RR=1.16;95%CI(1.07,1.26)]),ECG improvement rate([RR=1.25;95%CI(1.14,1.38)]),angina attack times([RR=-2.49;95%CI(-3.27,-1.70)]);fibrinogen([MD=-0.61;95%CI(-0.77,-0.45)]),plasma(specific)viscosity([MD=-0.19;95%CI(-0.22,-0.16)]),hematocrit([MD=-0.04;95%CI(-0.05,-0.03)])and other aspects were superior to the conventional treatment of Western medicine,the difference was statistically significant.Safety aspect:the reported adverse reactions were mild and tolerable events such as headache,dizziness,flush,etc.,no serious adverse events,and no separation from the report was found.Conclusion:on the basis of conventional western medicine,Xuesaitong injection can effectively improve the clinical efficacy,and has a high safety.However,due to the low quality of the included study and the small sample size,there is a potential bias in the study;therefore,the application and promotion of the research conclusions need to be cautious,and need to be further verified by more large sample,multicenter,double-blind clinical randomized controlled trials.
文摘Objective To evaluate the effect of Xuesai-tong injection (XSTI, 血塞通注射液 , a preparation of Panax Notoginseng) as auxilliary treatment of severe craniocerebral injury. Methods Eighty-seven patients with severe craniocerebral injury were selected and randomly divided into the treated group (n=44) and the control group (n = 43), they were treated with conventional treatment, and XSTI was given additionally to the treated group. Intracranial pressure (ICP) and Glasgow coma score (GCS) of all patients were measuredafter 1 or 2-week treatment, and Glasgow outcome scale (GOS) of them was determined 3 months later. Then the therapeutic effect in the two groups were compared. Results After treatment, the ICP was lower, GCS higher and GOS better in the treated group than those in the control group significantly, all showing statistical significance (P<0.05). Conclusion XSTI has marked clinical therapeutic effect in treating patients with severe craniocerebral injury.Original article on CJITWM (Chin) 2004 ;23 (3): 213
文摘目的:观察丁苯酞注射液联合血塞通注射液治疗急性脑梗死的临床疗效,同时采用MRI灌注成像从影像学角度进行疗效评价。方法:将符合纳入标准的80例急性脑梗死病人按随机数字表法随机分为对照组与治疗组,各40例。两组患者入院后均按照临床路径开展治疗,均给予降压、降糖、调脂、营养神经、抗血小板聚集等药物。对照组在此基础上联合应用丁苯酞氯化钠注射液100 mL静脉滴注治疗,观察组则在对照组基础上联合血塞通注射液200 mg加入5%葡萄糖注射液250 mL静脉滴注。对比两组患者入院当天、分组治疗10 d后的美国国立卫生研究院卒中量表(The National Institutes of Health Stroke Scale,NIHSS)评分、日常生活能力Barthel指数(Barthel Index,BI)评分以及给予MRI灌注成像相关指标变化。结果:治疗组治疗总有效率明显高于对照组(97.50%vs 77.50%,P<0.05);治疗后,两组NIHSS评分均较治疗前下降,BI评分均较治疗前上升,差异有统计学意义(P<0.05),且治疗组优于对照组(P<0.05);治疗后,两组感兴趣区的衰减指数均明显降低,平均扩散系数明显升高(P<0.05),且治疗组数据均明显优于对照组(P<0.05);分组治疗后,治疗组患者的脑血容量、脑血流量均明显优于对照组(P<0.05);基于Pearson相关性分析可知,治疗组治疗后平均扩散系数(r=-0.503,r=0.482)、衰减指数(r=-0.487,r=0.414)、脑血容量(r=-0.527,r=0.402)及脑血流量(r=-0.625,r=0.516)与NIHSS评分和BI评分均有显著相关性(P<0.05)。结论:基于多模态MRI成像结果可证实丁苯酞注射液联合血塞通注射液治疗急性脑梗死的效果良好,展现治疗前后病灶区域平均扩散系数和衰减指数的差异变化,直观反映容积比各向异性和部分各向异性的变化以及脑血流量和脑血容量的改善,且上述指标的变化与急性脑梗死患者的神经功能缺损程度和日常生活能力变化的相关性良好,提示多模态MRI成像结果可作为急性脑梗死的疗效评价提供可靠参考。
文摘Traumatic brain injury (TBI) is one of the most common diseases in clinical neurosurgery characterized with high incidence rate, mortality and many complications. Objectives: The purpose of this study is to explore the roles of Xuesaitong in the therapeutic effect of brain trauma and alteration of expression in Bax, a kind of promoting apoptosis factor. Methods: The rat traumatic brain injury models were established by using modified free falling body impact method. Thereafter, Xuesaitong was employed to be administered to TBI rats, and NSS Score Rating Scale was used to evaluate the effect of Xuesaitong. Moreover, real-time PCR was used to detect the Bax expression changes before and after the Xuesaitong administration. Results: Xuesaitong could accelerate the neurofunctional recovery of TBI rats, accompanied by NSS Scores significant decrease. Simultaneously, it also could inhibit the expression of Bax factor. Conclusions: Xusaitong could markedly ameliorate TBI restoration, in which it promotes the neurofunctional recovery, and at the same time it inhibits the expression of Bax.
基金Supported by Jiangxi Provincial Administration Bureau of Traditional Chinese Medicine (No. 020048, 2002A35)
文摘Objective： To investigate the neuro-protective effect of Xuesaitong Injection （血塞通注射液, XST） on brain inflammatory response after transient focal cerebral ischemia/reperfusion in rats. Methods： Focal cerebral ischemia/reperfusion models of male rats were induced by transient occlusion for 2 h of middle cerebral artery （MCA） which was followed by 24 h reperfusion. XST was administered through intraperitoneal injection of 25 mg/kg or 50 mg/kg at 4 h after the onset of ischemia. After reperfusion for 24 h, the neurological function score was evaluated, the brain edema was detected with dry-wet weight method, the myeloperoxidase （MPO） activity and the expression of intercellular adhesion molecule-1 （IOAM-l） of ischemic cerebral cortex and caudate putamen was determined by spectrophotometry and immunohistochemistry respectively. Results： XST not only lowered neurological function score at the dose of 50 mg/kg, but reduced brain edema and inhibited MPO activity and IOAM-1 expression as compared with the ischemia/reperfusion model group （P〈0.01）. Conclusion： XST has a definite effect on inhibiting the expression of IOAM-1 and neutrophil infiltration in rats with cerebral ischemia/reperfusion when treatment started at 4 h after ischemia onset, and also attenuates inflammation in the infarcted cerebral area.
文摘目的探讨血塞通冻干粉联合硫辛酸治疗糖尿病伴脑梗死的临床效果。方法选取2019年7月至2021年7月收治的110例糖尿病伴脑梗死患者为研究对象,根据入院单双号将其分为对照组(55例,丹参注射液+硫辛酸)和研究组(55例,血塞通冻干粉+硫辛酸)。比较两组的治疗效果。结果研究组的治疗总有效率高于对照组(P<0.05)。治疗后,研究组的空腹血糖(FBG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)、胰岛素抵抗指数(HOMA-IR)、可溶性细胞间黏附分子-1(sICAM-1)、白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、美国国立卫生院卒中量表(NIHSS)评分、全血黏度、红细胞压积、红细胞最大聚集指数及纤维蛋白原水平低于对照组,胰岛素分泌指数(HOMA-β)高于对照组(P<0.05)。结论相较于丹参注射液,血塞通冻干粉联合硫辛酸治疗糖尿病伴脑梗死的效果更优,其可改善胰岛功能,调节血糖水平及血液流变学指标,促进神经功能恢复。
